Dr. Thomas Stöhr
Managing Director

Thomas Stöhr is co-founder and Managing Director of A2M Pharma, a spin-off from the former Schwarz Pharma. He has more than 15 years experience in drug discovery and development and helped to bring several drugs and medical devices to the market. He is a trained CNS Pharmacologist and gained a lot of experience in preclinical and early clinical development of drugs for the treatment of neurological, immunological and infectious diseases.

Sectors of Personal Expertise: Pharmaceutical Research / Other Life Sciences / Disease/Disorders/Dependencies / Medical Products & Services / Therapeutics / Life Sciences

  A2M Pharma GmbH
Monheim, Germany

Neurology drug development spin-off from Schwarz Pharma

A2M Pharma is a spin-off from Schwarz Pharma following its merger with UCB. The two lead late stage preclinical projects focus on areas of high unmet medical need in Parkinson's disease: 1) quinpramine a lipid raft modulator for disease modification by inhibition of alpha-synuclein. This project is funded by the Michael J Fox Foundation 2) isorotigotine, an analogue of rotigotine (Neupro(R)) for the treatment of L-DOPA induced dyskinesias. This project is in collaboration with LTS Lohmann since isorotigotine will be administered by a transdermal system. A2M Pharma was founded in 2009 and is led by Pharma professionals with each member having >15years experience in biotech and Pharma industry: Thomas Stöhr with many years of experience in drug development, mainly pre-clinical and clinical development. Martin Donsbach, who has strong expertise in chemistry, CMC and regulatory affairs Michael Burnet with experience in business development, analytics and pharmacology.

Tags: drug development / neurology / spin-off

 Organisation Activities
Activity: private company (start-up/sme) with an innovative product, technology or service / a r&d or educational organisation active in
Technology Sectors: life sciences
Geographic: europe / germany